STOCK TITAN

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

NRx Pharmaceuticals (NASDAQ: NRXP) announced it will release its third quarter and year to date 2024 financial results after market close on Thursday, November 14, 2024. The company will host a conference call at 4:30 PM ET on the same day to discuss the results and provide a corporate update. The conference call will be accessible via webcast on the company's website and through telephone dial-in options for both domestic (+1-800-717-1738) and international (+1-646-307-1865) participants.

NRx Pharmaceuticals (NASDAQ: NRXP) ha annunciato che rilascerà i suoi risultati finanziari per il terzo trimestre e per l'anno fino ad oggi 2024 dopo la chiusura del mercato giovedì 14 novembre 2024. L'azienda ospiterà una conferenza telefonica alle 16:30 ET dello stesso giorno per discutere i risultati e fornire un aggiornamento aziendale. La conferenza sarà accessibile tramite webinario sul sito web dell'azienda e tramite opzioni di accesso telefonico sia per i partecipanti nazionali (+1-800-717-1738) che internazionali (+1-646-307-1865).

NRx Pharmaceuticals (NASDAQ: NRXP) anunció que publicará sus resultados financieros del tercer trimestre y del año hasta la fecha de 2024 después del cierre del mercado el jueves 14 de noviembre de 2024. La empresa llevará a cabo una llamada de conferencia a las 4:30 PM ET el mismo día para discutir los resultados y proporcionar una actualización corporativa. La llamada se podrá acceder a través de un webcast en el sitio web de la empresa y mediante opciones de marcación telefónica tanto para participantes nacionales (+1-800-717-1738) como internacionales (+1-646-307-1865).

NRx Pharmaceuticals (NASDAQ: NRXP)는 2024년 11월 14일 목요일 시장 종료 후 2024년 3분기 및 현재까지의 재무 결과를 발표할 것이라고 발표했습니다. 회사는 동일한 날 오후 4시 30분 ET에 결과를 논의하고 기업 업데이트를 제공하기 위해 전화 회의를 개최할 것입니다. 회의는 회사 웹사이트를 통한 웹캐스트 및 국내 (+1-800-717-1738) 및 국제 (+1-646-307-1865) 참가자들에 대한 전화 접속 옵션을 통해 접근할 수 있습니다.

NRx Pharmaceuticals (NASDAQ: NRXP) a annoncé qu'il publiera ses résultats financiers du troisième trimestre et de l'année à date 2024 après la fermeture du marché le jeudi 14 novembre 2024. L'entreprise organisera une conférence téléphonique à 16h30 ET le même jour pour discuter des résultats et fournir une mise à jour de l'entreprise. La conférence téléphonique sera accessible via un webinaire sur le site de l'entreprise et par des options de connexion téléphonique pour les participants nationaux (+1-800-717-1738) et internationaux (+1-646-307-1865).

NRx Pharmaceuticals (NASDAQ: NRXP) gab bekannt, dass es seine Finanzberichte für das dritte Quartal und das Jahr bis heute 2024 nach Börsenschluss am Donnerstag, den 14. November 2024, veröffentlichen wird. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen und ein Unternehmensupdate zu geben. Die Telefonkonferenz wird über ein Webcast auf der Unternehmenswebsite sowie über telefonische Einwahlinformationen sowohl für nationale (+1-800-717-1738) als auch für internationale (+1-646-307-1865) Teilnehmer zugänglich sein.

Positive
  • None.
Negative
  • None.

WILMINGTON, Del.  , Nov. 7, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter and year to date 2024 financial results after the market closes on Thursday, November 14, 2024, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. The Company will host a conference call to discuss the financial results as well as provide a corporate update at 4:30pm ET the same day.

A live webcast of the conference call will be available on the Company's website at https://ir.nrxpharma.com/events. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1-800-717-1738 or internationally +1-646-307-1865.  

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a healthcare delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:

Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-Chief Executive Officer, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-to-report-third-quarter-and-year-to-date-2024-financial-results-on-november-14-2024-302299343.html

SOURCE NRx Pharmaceuticals, Inc.

FAQ

When will NRXP release its Q3 2024 financial results?

NRx Pharmaceuticals (NRXP) will release its Q3 2024 financial results after market close on Thursday, November 14, 2024.

How can investors join NRXP's Q3 2024 earnings call?

Investors can join via webcast at ir.nrxpharma.com/events or by phone: domestic (+1-800-717-1738) or international (+1-646-307-1865) at 4:30 PM ET on November 14, 2024.

NRX Pharmaceuticals, Inc.

NASDAQ:NRXP

NRXP Rankings

NRXP Latest News

NRXP Stock Data

13.97M
10.75M
26.51%
4.75%
5.27%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WILMINGTON